AliveCor, the global leader in US FDA-cleared personal electrocardiogram (ECG) technology, today announced its entry in the Indian market with the revolutionary launch of the most clinically-validated personal ECG device, KardiaMobile 6L.
Owing to the accessibility challenges to quality healthcare in the country and COVID related infection fears, the portable and technology-enabled ECG device will help deliver affordable and convenient heart care to over 260 million heart patients and those at risk, without visiting a hospital.
* ECG pioneer AliveCor enters India with the world's only six-lead personal ECG device
* No hospital visits, no wires, no gels, no inconvenience; AliveCor's KardiaMobile 6L is in India
* India's heart care gets a big boost with the world's most clinically validated personal ECG device
* Introducing the only personal ECG devices that can detect the 3 most common arrhythmias
KardiaMobile 6L is the only personal ECG device in the world that can detect the three most common arrhythmias or irregular heartbeat-atrial fibrillation (AFib), bradycardia, and tachycardia, which require regular monitoring and a healthy lifestyle.
AliveCor's innovative technology gives patients the ability to record a medical-grade ECG in just 30 seconds, with no hospital visits and complete peace of mind.
The device is small enough to fit in a pocket, allowing users to check in on their hearts anytime, anywhere right from their smartphone.
In a country like India where over 70 per cent of the population owns a smartphone, this technology comes as a big boost to make heart care accessible, affordable, and convenient.
Across the world, cardiovascular disease (CVD) is the leading cause of mortality. According to The Lancet report, an estimated 54.5 million people are affected by CVD in India, leading to one in four deaths.
Reports also suggest that arrhythmias, like AFib, affect an estimated ten million people in India and are leading indicators of heart disease and stroke.
AliveCor's entry into India comes at an opportune time when the public is cautioned to stay at home and the condition of most patients suffering from heart abnormalities has been worsening.
While infection scare at hospitals is hampering regular check-ups, KardiaMobile 6L gives consumers the ability to keep track of their heart health from the comfort of home.
The pocket-sized, portable device enables clinicians to manage patients remotely. Considering the ongoing health crisis, the use of KardiaMobile 6L reassures optimal clinical control and caters to the need for efficient tools for safe out-of-hospital management.
For patients with pre-existing conditions or those who feel a symptom, it provides convenience to track heart health on-the-go without hospital visits.
"With hundreds of millions at risk for heart disease across the globe, accessible heart care has never been more important. AliveCor's expansion into India is pivotal to our mission of providing remote, medical-grade heart care to those who need it most. We are committed to innovating digital health services in India by offering patients the ability to take control of their own heart health from the comfort of home," mentioned Priya Abani, Chief Executive Officer, AliveCor.
As digital health emerges as a key objective for India where healthcare accessibility is a concern, mobile healthcare through a device like KardiaMobile 6L bears the utmost value.
AliveCor's Kardia devices have catered to nearly one million users, across 37 countries, and recorded more than 80 million ECGs till date. Early detection of arrhythmias is critical, and through the launch of KardiaMobile 6L, AliveCor puts the power of early detection directly into the hands of patients in India.
AliveCor's KardiaMobile 6L is priced at Rs 14000 and KardiaMobile is priced at Rs 8500. They are available for purchase at alivecor.in.
This story is provided by NewsVoir. ANI will not be responsible in any way for the content of this article.
DISCLAIMER
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU